Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445761 | 0.87 | ESRRG (0.55) | GAACA12CA1CA7CA14 | |
| SCHEMBL9971059 | 0.86 | GAA (0.51) | GAAMEN1KMT2ACACNA1BSMN1; SMN2 | |
| SCHEMBL6236607 | 0.86 | GAA (0.51) | GAAMEN1KMT2ACYP2C19PPARG | |
| SCHEMBL8203874 | 0.85 | RAB9A (0.56) | GAAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL1668799 | 0.84 | GAA (0.50) | GAAMEN1KMT2ASMN1; SMN2CA12 | |
| SCHEMBL13903558 | 0.84 | ESRRG (0.60) | GAAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL6347286 | 0.84 | GAA (0.72) | GAAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL4632779 | 0.84 | CA12 (0.60) | GAAMEN1KMT2ACYP1A2PPARG | |
| SCHEMBL13903494 | 0.84 | TSHR (0.57) | GAAMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL11995626 | 0.84 | GAA (0.51) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513811-B1 | NON-PEPTIDIC BRS-3 AGONISTS | SOLVAY PHARM GMBH (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7244743-B2 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1513811-A1 | NON-PEPTIDIC BRS-3 AGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104196-A1 | NON-PEPTIDIC BRS-3 AGONISTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
| US-5990135-A | FOR TREATING A RETROVIRAL INFECTION SUCH AS HIV INFECTION; FOR EXAMPLE 5S-N-((2-PYRIDINYL)METHOXYCARBONYL)VALINYLAMINO-2-((N-3 -PYRIDINYL)METHOXYCARBONYL)AMINO-4S-HYDROXY-1,6-DIPHENYL-2-AZAHEXANE AND OTHER COMPOUNDS OF GIVEN FORMULA | ABBOTT LABORATORIES (US) | 1999-11-23 | — | — | US | disclosed |
| US-5631376-A | PEPTIDE DERIVATIVES FOR TREATMENT OF AIDS | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| US-5621109-A | OXAZOLE/THIAZOLE DERIVATIVES OF HYDROXYMETHYL HYDRAZONES; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1997-04-15 | — | — | US | disclosed |
| US-5461067-A | For HIV infections | ABBOTT LABORATORIES (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171146-A1 | Non-peptidic BRS-3 agonists | BRS3, NPR3, ADRB3 | GAA 4589/4885MEN1 738/4885KMT2A 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.